Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445399 dose-finding study in moderate to severe hidradenitis suppurativa
2025-522695-83-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing SAR445399 with Placebo (2 arms). Primary endpoint: Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75. Planned start Apr 2026; status: authorised.
02
Drugs
SAR445399
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-522695-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522695-83-00.